Note: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

(Securities Code 7747)
September 8, 2026
(Commencement date of electronic provision measures: September 1, 2026)

To Our Shareholders:

Kenji Miyata
President & CEO
ASAHI INTECC CO., LTD.
3-100 Akatsuki-cho, Seto-shi, Aichi
489-0071 Japan

Notice of Convocation of the 50th Annual General Meeting of Shareholders

ASAHI INTECC CO., LTD. (the "Company") announces that the 50th Annual General Meeting of Shareholders of the Company will be held for the purposes as described below.

In convening this General Meeting of Shareholders, the Company provides information that constitutes the content of reference materials for the general meeting of shareholders, etc. in electronic format (the "matters subject to measures for providing information in electronic format"), which is posted on the internet. Please access the following websites to confirm the details.

The Company's website:
https://ir.asahi-intecc.co.jp/en/ir/stock/meeting.html
https://ir.asahi-intecc.co.jp/ja/ir/stock/meeting.html (in Japanese)

Tokyo Stock Exchange website (Listed Company Search):
https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show
https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show (in Japanese)

Please enter "ASAHI INTECC" in the "Issue name (company name)" field or the Company's securities code "7747" in the "Code" field to run a search, and select "Basic information" and then "Documents for public inspection/PR information" to confirm the details in the section of "Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting" under "Filed information available for public inspection."

Instead of attending this General Meeting of Shareholders in person, you may exercise your voting rights via internet or by mail. Please exercise your voting rights by either of these methods by 5:45 p.m. on Monday, September 28, 2026.

To Our Shareholders,

Marking the 50th Anniversary of Our Founding

Carrying Forward Our Legacy of Technology and Challenge to Drive the Next Stage of Growth

We would like to express our sincere gratitude to all our shareholders for your continued support.
This year marks the 50th anniversary of the Company's establishment on July 8, 1976. The progress we have made to date would not have been possible without the support of our shareholders, customers, business partners, and the many others who have supported the Asahi Intecc Group. We would like to express our sincere gratitude to all of you.
The Company began its business with the sale of ultra-fine stainless steel wire ropes. Building on the technologies cultivated in the industrial device field, we commercialized PCI guide wires and guiding catheters in 1992, marking our full-scale entry into the medical device field from 1994. Since then, we have sincerely addressed the needs of doctors and customers and delivered our proprietary technologies and products around the world.

The 50th anniversary of our founding is both an important milestone and a new starting point for our next stage of growth. We will continue to steadily enhance our product competitiveness, expand our market share, improve productivity, and reinforce our global business foundation. At the same time, we will leverage the technologies and business foundation we have developed over the years to continue taking on challenges in new treatment areas, product fields, and technologies.
As the scale and geographic reach of our business continue to expand, we will further strengthen our management structure to facilitate the sharing of knowledge and expertise across the Group and enable each division and region to fulfill its respective role.

Effective July 2026, the Company has adopted a management structure with two representative directors: the Representative Director and Chairman and the Representative Director, President & CEO. While sharing a common understanding of the Company's medium- to long-term management direction, we will each fulfill our respective roles. The Representative Director and Chairman will work to create new business opportunities and build key external relationships, drawing on extensive management experience and industry networks. The Representative Director, President & CEO will oversee the overall management of the Group and work to grow existing businesses, strengthen profitability, and reinforce the management foundation through the formulation of medium- to long-term management policies and the steady implementation of the medium-term management plan.
By bringing together the capabilities of the Representative Director and Chairman, the Representative Director, President & CEO, and all Group companies and divisions, we will strive to further enhance corporate value.

The Asahi Intecc Group will continue to regard "technology development" as its lifeblood and deliver products that contribute to improving the quality of life (QOL) of patients around the world. We will pass on to the next generation the technologies we have developed and the trust we have earned over the past 50 years, and strive to remain a company that is needed by society and that continues to grow sustainably.
We ask for your continued understanding and support.

Sincerely,

Masahiko Miyata, Chairman

Kenji Miyata, President & CEO

1. **Date and Time:** Tuesday, September 29, 2026 at 10:00 a.m.
2. **Place:** "Main Hall" on the 3rd floor of Nagoya Convention Hall located at Global Gate, 4-60-12 Hiraike-cho, Nakamura-ku, Nagoya-shi, Aichi, Japan
3. **Meeting Agenda:**

Matters to be reported:

1. The Business Report, Consolidated Financial Statements for the Company's 50th Fiscal Year (from July 1, 2025, to June 30, 2026), and results of audits of the Consolidated Financial Statements by the Accounting Auditor and the Audit and Supervisory Committee
2. Non-consolidated Financial Statements for the Company's 50th Fiscal Year (from July 1, 2025, to June 30, 2026)

Matters to be resolved:

Proposal 1: Appropriation of Surplus

Proposal 2: Election of Nine (9) Directors (excluding Directors who are Audit and Supervisory Committee Members)

Proposal 3: Election of Three (3) Directors who are Audit and Supervisory Committee Members

Proposal 4: Election of One (1) Director who is a Substitute Audit and Supervisory Committee Member

4. **Matters decided upon convocation:**

(1) Among the matters subject to measures for providing information in electronic format, certain portions of the business report, as well as consolidated financial statements, non-consolidated financial statements, the Accounting Auditor's audit report, and the Audit and Supervisory Committee's audit report, are not included in the documents to be delivered to shareholders who make request for the delivery of hard copies, based on laws and regulations and Article 14 of the Articles of Incorporation of the Company. Accordingly, the documents delivered to shareholders constitute a portion of the documents audited by the Audit and Supervisory Committee in preparing its audit report.

(2) If you exercise your voting rights both via internet and in writing, the vote exercised via internet shall be treated as valid.
Moreover, if you exercise your voting rights multiple times via internet, the vote made last shall be treated as valid.

(3) If there is no indication of a vote for or against any proposal on a returned voting rights exercise form, it will be treated as an indication of a vote for the proposal.

◎ Any revisions to the matters subject to measures for providing information in electronic format will be provided as detailed before and after the revisions on the websites listed on the preceding page.

◎ Souvenirs will not be provided to shareholders attending the General Meeting of Shareholders, in light of fairness, etc., between shareholders who visit the venue and those who have difficulty visiting the venue. The Company thanks you for your understanding.

5. **Instructions for Exercising Voting Rights:** There are three ways to exercise your voting rights as described below:

Attending the Annual General Meeting of Shareholders

Present the enclosed voting rights exercise form to the receptionist at the meeting.

Date and Time: Tuesday, September 29, 2026, at 10:00 a.m.

(1) Mailing the voting rights exercise form

Complete the enclosed voting rights exercise form by indicating your vote for or against each of the agenda items and return it.

Votes to be received by Monday, September 28, 2026, at 5:45 p.m.

(2) Exercising voting rights via internet

Review the following Guidance for Exercising Voting Rights via the Internet, and follow the instructions on the screen to vote on the agenda items.

Votes to be cast by Monday, September 28, 2026, at 5:45 p.m.

Note: The following website is available for use only in the Japanese language and by registered shareholders in Japan.

Inquiries regarding the operation of the voting rights exercise website:

Mitsubishi UFJ Trust and Banking Corporation, Corporate Agency Division

Toll free (within Japan) 0120-173-027 (Hours of operation: 9:00 a.m. to 9:00 p.m., free of charge)

To Institutional Shareholders:

Institutional investors that have applied in advance to use the voting rights exercise platform operated by ICJ, Inc. may exercise voting rights via said platform.

Guidance for Exercising Voting Rights via the Internet

If you exercise your voting rights via the internet, please access the voting rights exercise website using a smartphone or personal computer, etc., and exercise your voting rights by following the on-screen instructions.

Exercise deadline: Votes received by Monday, September 28, 2026, at 5:45 p.m.

Method by scanning the QR Code using a smartphone

You can log into the voting website by scanning the "Login QR Code" without entering the "Login ID" and "Temporary Password."

1. Scan the QR Code
   With your smartphone, please scan the "Login QR Code" printed on the side slip (right side) of the enclosed voting rights exercise form.

2. Select the method to exercise your voting rights
   The exercise method selection screen appears. Please select a method to exercise your voting rights.

3. Select approval or disapproval for each proposal
   Please select your vote for or against each of the proposals by following the on-screen instructions.

Exercise is completed by following the on-screen instructions.

Method by entering Login ID and Temporary Password using a personal computer

Voting rights exercise website: https://evote.tr.mufg.jp/
(QR code is a registered trademark of DENSO WAVE INCORPORATED.)

1. Access the voting rights exercise website

   Click "Next screen"

2. Enter the "Login ID" and "Temporary Password" indicated on the side slip (right side) of the enclosed voting rights exercise form, and click "Login"

   Click "Login"

From here, please vote for or against the proposals by following the on-screen instructions.

Information on Acceptance of Preliminary Questions

Question to be received by: Thursday, September 17, 2026, at 5:00 p.m.
Send to: shitsumon@asahi-intecc.com
Method for sending: Please include the following items in the text of the e-mail.

"Shareholder number" (8-digit number)
Of the 15-digit number on the voting rights exercise form, the middle 8-digit number is your shareholder number.
"Name or corporate name (if a corporation, please indicate name of department, title, and name of the person sending the question)"
"Description of question"

Among the questions received, the Company will answer questions that are deemed to be of particular interest to shareholders on the day of the General Meeting of Shareholders. We will report the details of the briefing at the meeting by e-mail to shareholders who have sent preliminary questions.

To Shareholders Receiving Dividends at Post Office Counters

For prompt, safe, and secure receipt of your dividends, the Company recommends payment by direct deposit into an account. If you choose direct deposit, your dividends will be deposited into your designated account on the first day of dividend payment.
To change the method by which you receive your dividends, please complete the necessary procedures through the securities company where you hold your shares.

When receiving dividends through a securities company
You can receive your dividends in your account with the securities company where your shares are held.

When receiving dividends in a bank account
You can receive your dividends in your designated bank account.

Proposals and References

Proposal 1: Appropriation of Surplus

Regarding the distribution of earnings, the Company considers the return of earnings to shareholders to be one of the most important management issues and the payment of stable dividends on a continuing basis to be its basic policy.

We calculate the amount of dividends based on a long-term perspective and in comprehensive consideration of consolidated financial results for the fiscal year under review, future outlooks, the level of internal reserves, etc., targeting a consolidated dividend payout ratio of 35%.

Regarding the year-end dividends for the fiscal year under review, the Company proposes to pay an ordinary dividend of ¥42.21 per common share (consolidated dividend payout ratio of 35.0%). In addition, to commemorate the 50th anniversary of the Company's establishment and to express its gratitude to shareholders for their support over the years, the Company proposes to add a commemorative dividend of ¥6.03 per common share (consolidated dividend payout ratio of 5.0%), for a total year-end dividend of ¥48.24 per common share.

Matters regarding year-end dividends

1. Type of dividend property
   Cash

2. Matters regarding allotment of dividend property to shareholders and its total amount
   ¥48.24 per common share of the Company
   (ordinary dividend: ¥42.21; commemorative dividend: ¥6.03)
   Total amount: ¥12,799,245,342

3. Effective date of distribution of surplus
   Wednesday, September 30, 2026

Trends of dividends

	47th term	48th term	49th term	50th term
Dividend	¥14.48	¥20.37	¥24.23	¥48.24



Proposal 2: Election of Nine (9) Directors (Excluding Directors Who Are Audit and Supervisory Committee Members)

The term of office of all nine (9) Directors (excluding Directors who are Audit and Supervisory Committee Members) will expire at the conclusion of this Annual General Meeting of Shareholders. Accordingly, the election of nine (9) Directors (excluding Directors who are Audit and Supervisory Committee Members) is proposed.
The candidates for Directors (excluding Directors who are Audit and Supervisory Committee Members) are listed as follows:

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="2">1</td><td>Masahiko Miyata
(March 15, 1967)

[Reappointment]</td><td>November 1994

December 1995
March 1999

July 2000
September 2001
September 2003

March 2004
March 2006

August 2006
June 2007
September 2009

July 2016
April 2023

September 2024
June 2025

September 2025
July 2026</td><td>Joined the Company, General Manager of Planning Office, Supervisory Division
Director, General Manager of Corporate Planning Department
Executive Director, Assistant to General Manager of Medical Division and General Manager of Production Engineering Department
General Manager of Medical Division
Senior Executive Director
Director of ASAHI INTECC THAILAND CO., LTD. (current position)
Executive Vice President and Representative Director
President & CEO of CompassMed Integration Co., Ltd. (currently ASAHI INTECC J-sales, INC.)
Director of ASAHI INTECC HANOI CO., LTD. (current position)
CEO of ASAHI INTECC THAILAND CO., LTD.
President & CEO
President & CEO of Filmecc Co., Ltd.
Director of Filmecc Co., Ltd.
Representative Director and President of Magnaire Co., Ltd. (current position)
Chairman and Director
Chairman of the Medical Technology Association of Japan (current position)
Vice Chairman of the Japan Federation of Medical Devices Associations (current position)
Director of ASAHI INTECC J-sales, INC. (current position)
Representative Director and Chairman (current position)
Representative Director and Chairman of ASAHI SURGICAL ROBOTICS CO., LTD. (current position)
Chairman of ASAHI INTECC USA, INC. (current position)
Chairman of Filmecc USA, Inc. (current position)</td><td>5,823,800</td><td>13/13
(100%)</td></tr>
<tr><td colspan="5">[Reason for nomination as candidate for Director]

Having served as President & CEO for the period from 2009 to 2024, Mr. Masahiko Miyata drove the Company’s group management and appropriately fulfilled the role of enhancing the Company’s corporate value with his global management perspective, speedy decision-making, and good relationships built with medical professionals, partners, and other stakeholders. At present, as Representative Director and Chairman, he oversees the Group’s entire business and contributes to reinforcing our presence through activities in industrial organizations. He has been renominated as Director in expectation of his further contribution going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="2">2</td><td>Kenji Miyata
(July 16, 1970)

[Reappointment]</td><td>April 1993 Joined the Company
January 1997 Executive Vice President and Director of ASAHI INTECC THAILAND CO., LTD.
July 1997 Director
July 2000 Executive Officer
August 2002 Deputy General Manager of Device Division
September 2003 Director
July 2006 General Manager of Device Division
September 2010 Executive Director
July 2011 President & CEO of ASAHI INTECC GMA Co., Ltd.
September 2013 President & CEO of Toyoflex Corporation
January 2015 Director of ASAHI INTECC THAILAND CO., LTD. (current position)
September 2015 Executive Vice President and Director
July 2016 General Manager of Quality Assurance Division
Chairman and Director of ASAHI INTECC HANOI CO., LTD. (current position)
September 2016 Executive Vice President and COO
July 2017 Director of TOYOFLEX CEBU CORPORATION (current position)
July 2018 Director of FICUS Co., Ltd.
July 2020 General Manager of Device Business Division
May 2022 Director of walkey Inc. (current position)
September 2022 Director of Filmecc Co., Ltd.
Director of Nihon Chemical Coat Co., Ltd.
January 2023 President & CEO of LAKE R&D Inc.
July 2024 General Manager of Production Division
September 2024 President & CEO (current position)</td><td>5,077,200</td><td>13/13
(100%)</td></tr>
<tr><td colspan="4">[Reason for nomination as candidate for Director]

Mr. Kenji Miyata is well versed in production technology for stainless steel processing, the source of the Company’s technology, as well as restructuring of an acquired company. As Executive Vice President and COO since 2016, and as President & CEO since 2024, he has driven the Company’s group management and appropriately fulfilled the role of enhancing the Company’s corporate value. He has been renominated as Director in expectation of his further contribution going forward as a leader of the Group.</td></tr>
</table>

No.	Name (Date of birth)	Career summary, positions and responsibilities in the Company, and significant concurrent positions		Number of company shares held	Status of attendance at the Board of Directors
3	Makoto Nishiuchi (August 15, 1964) [Reappointment]	October 2005 July 2008 May 2010 July 2015 July 2016 January 2017 October 2017 July 2018 September 2018 July 2019 July 2022 July 2024 September 2024	Joined the Company Deputy Group Manager of Medical Research and Development Group, Medical Division Group Manager of Medical Research and Development Group, Medical Division Executive Officer Director of ASAHI INTECC USA, INC. (current position) Chief Research and Development Officer Senior Executive Officer Director of RetroVascular Inc. (currently ASAHI Medical Technologies, Inc.) (current position) Director General Manager of Medical Brand Business Unit of Medical Business Division (current position) Chief Digital Officer (current position) Deputy General Manager of Medical Business Division General Manager of Medical Business Division (current position) Executive Director (current position)	48,400	13/13 (100%)
	[Reason for nomination as candidate for Director] Since joining the Company, Mr. Makoto Nishiuchi has consistently been engaged in the Medical Division and contributed to the development of medical devices. With his abundant experience and track record in the R&D and technology-related fields, he currently works as General Manager of Medical Business Division and is appropriately fulfilling the role of enhancing the Company’s corporate value. He has been renominated as candidate for Director in expectation of his further contribution going forward.				

No.	Name (Date of birth)	Career summary, positions and responsibilities in the Company, and significant concurrent positions	Number of company shares held	Status of attendance at the Board of Directors
4	Yoshinori Terai (September 13, 1963) [Reappointment]	October 1998 Joined the Company July 2004 President & CEO of ASAHI INTECC USA, INC. September 2008 Executive Officer April 2012 Director of ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd. September 2013 Director (current position) July 2016 Director of ASAHI INTECC J-sales, INC. July 2019 General Manager of New Business Development Division (current position) February 2020 Director of ASAHI INTECC CIS LLC Director of ASAHI INTECC EUROPE B.V. (current position) July 2020 Supervisor of Global Sales and Marketing of Medical Brand Business Unit of Medical Business Division Director of ASAHI INTECC Deutschland GmbH (current position) June 2021 President & CEO of Filmecc USA, Inc. (current position) July 2021 President & CEO of Pathways Medical Corporation (current position) Director of Rev. 1 Engineering, Inc. (current position) April 2023 Director of Magnaire Co., Ltd. (current position) December 2023 President & CEO of ASAHI Medical Technologies, Inc. (current position) July 2026 Director of ASAHI INTECC USA, INC. (current position)	162,000	13/13 (100%)
	[Reason for nomination as candidate for Director] Mr. Yoshinori Terai has been engaged in the Overseas Sales unit for medical devices for many years and has contributed to the Company's global development. Leveraging his broad perspective and extensive network, he currently serves as General Manager of New Business Development Division and is appropriately fulfilling the role of enhancing the Company's corporate value. He has been renominated as Director in expectation of his further contribution going forward.			

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="2">5</td><td>Mizuho Ito
(September 8, 1973)

[Reappointment]</td><td>May 2003 Joined the Company
May 2005 Deputy General Manager of Corporate Strategic Office
April 2008 Auditor of ASAHI INTECC HANOI CO., LTD.
September 2008 General Manager of Corporate Strategic Office (current position)
September 2009 Auditor of GMA Co., Ltd.
October 2010 Auditor of Filmecc Co., Ltd.
April 2012 Auditor of ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd. (current position)
September 2013 Director of Toyoflex Corporation
December 2013 Group Manager of Accounting Group, Administration Division
July 2015 Executive Officer
July 2016 General Manager of Administration Division (current position), Auditor of ASAHI INTECC J-sales, INC. (current position)
September 2016 Director and CFO (current position)
July 2018 Director of RetroVascular Inc. (currently ASAHI Medical Technologies, Inc.)
July 2021 Director of A-Traction Inc. (currently ASAHI SURGICAL ROBOTICS CO., LTD.) (current position)
April 2023 Director of Magnaire Co., Ltd. (current position)
April 2025 Auditor of Asahi Intecc Medical Device (Nanning) Co., Ltd. (current position)</td><td>38,300</td><td>13/13
(100%)</td></tr>
<tr><td colspan="4">[Reason for nomination as candidate for Director]

As General Manager of Corporate Strategic Office, Ms. Mizuho Ito has been engaged in finance, accounting, IR, and M&A projects for many years. She is currently serving as General Manager of Administration Division, leading efforts to strengthen the function of the Head Office as head of the Company’s Corporate unit, and is appropriately fulfilling the role of enhancing the Company’s corporate value. She has been renominated as candidate for Director in expectation of her further contribution going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="2">6</td><td>Kazuhito Ishihara
(June 24, 1961)

[Reappointment]</td><td>February 2018 Joined the Company
February 2018 Supervisor of Medical Research and Development, Medical Division
September 2018 Executive Officer
July 2019 Deputy Supervisor of Research and Development of Medical Brand Business Unit of Medical Business Division
September 2019 General Manager of Clinical Development Office of Medical Business Division
July 2024 Deputy General Manager of Research Division
September 2024 Director (current position)
July 2026 Deputy General Manager of Medical Business Division (current position)
Supervisor of Research and Development of Medical Brand Business Unit of Medical Business Division (current position)</td><td>3,868</td><td>13/13
(100%)</td></tr>
<tr><td colspan="4">[Reason for nomination as candidate for Director]

Since joining the Company, Mr. Kazuhito Ishihara has consistently been engaged in the Medical Division and contributed to the development of medical devices. With his abundant experience and track record in the R&D and technology-related fields, he works as Deputy General Manager of Medical Business Division, and is appropriately fulfilling the role of enhancing the Company’s corporate value. He has been renominated as candidate for Director in expectation of his further contribution going forward.</td></tr>
<tr><td rowspan="2">7</td><td>Shinjiro Otani
(September 9, 1975)

[Reappointment]</td><td>November 2002 Joined the Company
July 2016 Director of Toyoflex Corporation
July 2021 General Manager of President’s Office
May 2022 Auditor of walkey Inc. (current position)
July 2023 Group Manager of Human Resources Development Group (current position)
October 2023 Executive Officer
September 2024 President & CEO of LAKE R&D Inc.
Director of FICUS Co., Ltd. (current position)
January 2025 Director of Nitta Mold Co., Ltd.
September 2025 Director (current position)
Director of LAKE R&D Inc. (current position)
October 2025 General Manager of Human Resources Development Division (current position)</td><td>30,900</td><td>10/10
(100%)</td></tr>
<tr><td colspan="4">[Reason for nomination as candidate for Director]

Since joining the Company, Mr. Shinjiro Otani has been engaged in a wide variety of fields including finance and accounting, overseas factory accounting, production management, management of an acquired subsidiary and personnel management, and, at present, he works as General Manager of the Human Resources Development Division, and is appropriately fulfilling the role of enhancing the Company’s corporate value. He has been renominated as candidate for Director in expectation of his further contribution going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="3">8</td><td>Takahiro Kusakari
(March 14, 1979)

[Reappointment]
[Outside]
[Independent]</td><td>July 2007
October 2008
November 2010
January 2013
June 2015

July 2022
September 2022
March 2023
June 2023
April 2026</td><td>Joined SBI Real Marketing Co., Ltd.
Joined Sawakami Asset Management Inc.
Fund Manager of Sawakami Asset Management Inc.
Chief Investment Officer of Sawakami Asset Management Inc.
Director and Chief Investment Officer of Sawakami Asset Management Inc.
Joined Sawakami Holdings, Inc
Outside Director of the Company (current position)
Joined Japan Catalyst, Inc.
Director and Co-President of Japan Catalyst, Inc.
Executive Officer and General Manager of Equity Investment Department of Monex Asset Management, Inc. (current position)</td><td>800</td><td>13/13
(100%)</td></tr>
<tr><td colspan="5">[Matters regarding independence]
The Company has registered Mr. Takahiro Kusakari as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange. If the election of Mr. Kusakari is approved, he will continue to serve as an Independent Director.</td></tr>
<tr><td colspan="5">[Reason for nomination as candidate for Outside Director and Overview of Expected Roles]

Mr. Takahiro Kusakari has served as Fund Manager and Chief Investment Officer of an investment trust management firm and has been offering suggestions for improving the Company’s corporate value based on his experience in corporate analysis gained through dialogue with countless companies.
He will have served as Outside Director for four (4) years at the conclusion of this Annual General Meeting of Shareholders and he has been renominated as candidate for Outside Director in expectation of his contribution to strengthening the supervision of business execution through accurate advice based on his extensive experience in corporate analysis going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th>Career summary, positions and responsibilities in the Company,
and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th></tr>
<tr><td rowspan="3">9</td><td>Akihiro Taguchi
(January 26, 1958)

[Reappointment]
[Outside]
[Independent]</td><td>April 1980 Joined Olympus Optical Co., Ltd. (currently Olympus Corporation)
June 2010 Corporate Executive Officer of Olympus Corporation
April 2012 Senior Corporate Managing Officer of Olympus Corporation
President and Representative Director of Olympus Medical Systems Corp.
April 2013 Outside Director of Sony Olympus Medical Solutions Inc.
April 2015 Head of Sales & Marketing Group and Business Management Officer of Medical Business of Olympus Corporation
June 2015 Director and Senior Corporate Managing Officer of Olympus Corporation
April 2019 Executive Officer and COO of Olympus Corporation
April 2020 Executive Officer and CTO of Olympus Corporation
August 2022 Independent Director of SATORI ELECTRIC CO., LTD.
September 2023 Outside Director of the Company (current position)
April 2026 Outside Director of MIRAINI HOLDINGS CO., LTD. (current position)</td><td>500</td><td>13/13
(100%)</td></tr>
<tr><td colspan="4">[Matters regarding independence]
The Company has registered Mr. Akihiro Taguchi as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange. If the election of Mr. Taguchi is approved, he will continue to serve as an Independent Director. Transaction amounts between the Company and Olympus Corporation, for which he served as Executive Officer and CTO until March 31, 2022, are less than 1% of consolidated net sales in the consolidated financial statements of the Company. Accordingly, the Company has determined that it is not a “major business partner” within the meaning of the independence criteria stipulated in the Securities Listing Regulations of the Tokyo Stock Exchange.</td></tr>
<tr><td colspan="4">[Reason for nomination as candidate for Outside Director and Overview of Expected Roles]

Mr. Akihiro Taguchi has supervised the management of the Company and offered suggestions for improving the Company’s corporate value, based on his ample experience and broad insight in the medical industry including serving as President and Representative Director of Olympus Medical Systems Corp.
He will have served as Outside Director for three (3) years at the conclusion of this Annual General Meeting of Shareholders and he has been renominated as candidate for Outside Director in expectation of his contribution to strengthening the supervision of business execution through accurate advice based on his extensive experience in corporate management going forward.</td></tr>
</table>

(Notes)

1. There is no special interest between the above candidates for Directors and the Company.
2. Ms. Mizuho Ito’s name on the family register is Mizuho Onogi.
3. Messrs. Takahiro Kusakari and Akihiro Taguchi are candidates for Outside Directors.
4. The Company has entered into agreements with Messrs. Takahiro Kusakari and Akihiro Taguchi to limit their liability for damages stipulated in Article 423, Paragraph 1 of the Companies Act pursuant to the provision of Article 427, Paragraph 1 of the said Act. The limit of liability under such agreement shall be the amount prescribed by laws and regulations. If the reelection of Messrs. Kusakari and Taguchi is approved, the Company will continue the agreements under the same terms and conditions. The overview of the content of the agreement is as follows.
   - If an Outside Director is liable for any damage to the Company attributable to negligence of his duties, his liability shall be limited to the minimum liability amount specified in Article 425, Paragraph 1 of the Companies Act.
   - The aforementioned liability limitation shall be applied only in cases where such an Outside Director has executed his duties that have caused the liability in good faith and without gross negligence.
5. The Company has concluded a liability insurance contract with an insurance company for directors and officers. The relevant insurance policy covers damages and legal expenses incurred by the insured due to claims for damages arising from acts (including omissions) committed by the insured in connection with his/her duties as an officer of the Company. All insurance premiums are paid by the Company. If this proposal is approved and each candidate assumes the office of Director, he/she will be included as an insured person under the relevant insurance policy. In addition, the Company plans to renew the policy with the same contents at the next renewal.
6. The number of shares held by the above candidates for Directors is as of June 30, 2026.

7. CompassMed Integration Co., Ltd changed its name to ASAHI INTECC J-sales, INC. in January 2010.
8. GMA Co., Ltd. changed its name to ASAHI INTECC GMA Co., Ltd. from July 2010. The Company acquired ASAHI INTECC GMA Co., Ltd. through an absorption-type merger on October 1, 2013.
9. RetroVascular, Inc. changed its name to ASAHI Medical Technologies, Inc. in December 2018.
10. A-Traction Inc. changed its name to ASAHI SURGICAL ROBOTICS CO., LTD. in August 2021.
11. The Company acquired all shares of LAKE R&D Inc., making it a wholly owned subsidiary on January 5, 2023.
12. The Company acquired Toyoflex Corporation through an absorption-type merger on July 1, 2023.
13. Magnaire Co., Ltd. was established on April 3, 2023 as a joint venture company, in which the Company holds a 60% stake. The Company acquired all shares of Magnaire Co., Ltd., making it a wholly owned subsidiary on June 2, 2023.
14. The Company acquired all shares of Nitta Mold Co., Ltd., making it a wholly owned subsidiary on January 6, 2025.

Proposal 3: Election of Three (3) Directors Who Are Audit and Supervisory Committee Members

The term of office of all three (3) Directors who are Audit and Supervisory Committee Members will expire at the conclusion of this Annual General Meeting of Shareholders. Accordingly, the election of three (3) Directors who are Audit and Supervisory Committee Members is proposed.
The Audit and Supervisory Committee has previously given its consent regarding this Proposal.
The candidates for Directors who are Audit and Supervisory Committee Members are as follows:

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, positions and responsibilities in the Company, and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th><th>Status of attendance at the Audit and Supervisory Committee</th></tr>
<tr><td rowspan="3">1</td><td>Ryuji Tomida
(April 3, 1975)

[Reappointment]
[Outside]
[Independent]</td><td>October 2001

April 2006

December 2006
October 2007

April 2010
April 2011
May 2011

April 2013

April 2016
September 2016

September 2018

April 2020

December 2021

June 2024

December 2025</td><td>Registered with Nagoya Bar Association (currently Aichi Bar Association)
Joined Higashi Sakura Law Firm
Part-Time Lecturer at Law Department, Nagoya University of Economics
Nagoya Municipal Advisor (current position)
Opened Tomida & Yamauchi Law Firm (currently Yomei law office)
Member of Research Office of Aichi Bar Association
Part-Time Lecturer at Aichi Law School
Member of Japan Federation of Bar Associations Inquiry System Committee (current position)
Member of Kasugai City Information Disclosure & Personal Information Protection Committee
Vice President of Aichi Bar Association
Substitute Audit and Supervisory Committee Member of the Company
Outside Director of the Company (Audit and Supervisory Committee Member) (current position)
General Manager of Aichi Bar Association Inquiry Research Office
Public Interests Member of Aichi Prefectural Labour Relations Commission (current position)
Member of Aichi Prefectural Land Expropriation Commission (current position)
Chairperson of Aichi Prefectural Labour Relations Commission (current position)</td><td>2,000</td><td>13/13
(100%)</td><td>14/14
(100%)</td></tr>
<tr><td colspan="6">[Matters regarding independence]
The Company has registered Mr. Ryuji Tomida as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange. If the election of Mr. Tomida is approved, he will continue to serve as an Independent Director.</td></tr>
<tr><td colspan="6">[Reason for nomination as candidate for Outside Director who is an Audit and Supervisory Committee Member and Overview of Expected Roles]

Mr. Ryuji Tomida has expertise and ample experience as a lawyer and appropriately fulfills the duties of Outside Director who is an Audit and Supervisory Committee Member by providing advice for and checking on the Company’s business execution from the perspective of a legal expert.
He will have served as Outside Director who is an Audit and Supervisory Committee Member for eight (8) years at the conclusion of this Annual General Meeting of Shareholders and has been renominated as candidate for Outside Director who is an Audit and Supervisory Committee Member in expectation of his further contribution going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, positions and responsibilities in the Company, and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th><th>Status of attendance at the Audit and Supervisory Committee</th></tr>
<tr><td rowspan="3">2</td><td>Ryoko Fukaya
(May 12, 1973)

[Reappointment]
[Outside]
[Independent]</td><td>October 1999
April 2003
August 2007
April 2011
June 2016

March 2017
June 2019

September 2020

September 2022

April 2023

July 2023

June 2026</td><td>Joined Chuo Audit Corporation
Registered as a Certified Public Accountant
Joined KPMG AZSA LLC
Opened Ryoko Fukaya Accounting Office
Secretary of Tokai Association, the Japanese Institute of Certified Public Accountants
Registered as a Certified Tax Accountant
Chairwoman of the Public Relations Committee of the Japanese Institute of Certified Public Accountants Tokai Association
Substitute Audit and Supervisory Committee Member of the Company
Outside Director of the Company (Audit and Supervisory Committee Member) (current position)
Auditor of Incorporated Educational Institution Sugiyama Jogakuen (current position)
Part-Time Researcher at Graduate School of Management, Kyoto University
Outside Director (Audit and Supervisory Committee Member) of Aica Kogyo Company, Limited (current position)</td><td>1,000</td><td>13/13
(100%)</td><td>14/14
(100%)</td></tr>
<tr><td colspan="6">[Matters regarding independence]
The Company has registered Ms. Ryoko Fukaya as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange. If the election of Ms. Fukaya is approved, she will continue to serve as an Independent Director.</td></tr>
<tr><td colspan="6">[Reason for nomination as candidate for Outside Director who is an Audit and Supervisory Committee Member and Overview of Expected Roles]

Ms. Ryoko Fukaya appropriately fulfills the duties of Outside Director who is an Audit and Supervisory Committee Member such as monitoring the Company’s overall management using her expertise and ample experience as a certified public accountant and by providing advice for and checking on the Company’s business execution.
She will have served as Outside Director who is an Audit and Supervisory Committee Member for four (4) years at the conclusion of this Annual General Meeting of Shareholders and has been renominated as candidate for Outside Director who is an Audit and Supervisory Committee Member in expectation of her further contribution going forward.</td></tr>
</table>

<table>
<tr><th>No.</th><th>Name
(Date of birth)</th><th colspan="2">Career summary, positions and responsibilities in the Company, and significant concurrent positions</th><th>Number of company shares held</th><th>Status of attendance at the Board of Directors</th><th>Status of attendance at the Audit and Supervisory Committee</th></tr>
<tr><td rowspan="3">3</td><td>Shigeki Moriguchi
(July 23, 1957)

[Reappointment]
[Outside]
[Independent]</td><td>April 1981
March 2001

November 2006

April 2009

June 2011

April 2019

June 2021

April 2022
September 2022

September 2024</td><td>Joined The Tokai Bank, Ltd. (currently MUFG Bank, Ltd.)
Deputy General Manager of Operations Planning Division of UFJ Holdings, Inc. (currently Mitsubishi UFJ Financial Group, Inc.)
Member of the Board, General Manager of Human Resources Division of The Bank of Tokyo-Mitsubishi UFJ, Ltd. (currently MUFG Bank, Ltd.)
Member of the Board, General Manager of Shin-Nagoya Ekimae Branch of The Bank of Tokyo-Mitsubishi UFJ, Ltd. (currently MUFG Bank, Ltd.)
Managing Executive Officer of Mitsubishi UFJ Research and Consulting Co., Ltd.
Managing Director of Aichi-ken Credit Guarantee Corporation
Part-time Audit & Supervisory Board Member of Credit Guarantee Servicer Inc.
Advisor of Aichi-ken Credit Guarantee Corporation
Substitute Audit and Supervisory Committee Member of the Company
Outside Director of the Company (Audit and Supervisory Committee Member) (current position)</td><td>400</td><td>13/13
(100%)</td><td>14/14
(100%)</td></tr>
<tr><td colspan="6">[Matters regarding independence]
The Company has registered Mr. Shigeki Moriguchi as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange. If the election of Mr. Moriguchi is approved, he will continue to serve as an Independent Director.
While Mr. Moriguchi is a former employee of MUFG Bank, Ltd., one of the Company's creditors, he has been retired from the bank for over ten years. Therefore, the Company has determined that there are no conflicts with the independence standards set forth in the listing regulations established by the Tokyo Stock Exchange and that there is no risk of affecting his independence. Furthermore, the Company has confirmed that there was no business relationship between the Company and the sector he was in charge of at that time.</td></tr>
<tr><td colspan="6">[Reason for nomination as candidate for Outside Director who is an Audit and Supervisory Committee Member and Overview of Expected Roles]

Mr. Shigeki Moriguchi appropriately fulfills the duties of Outside Director who is an Audit and Supervisory Committee Member, such as by providing advice for and checking on the Company's business execution, using his wide-ranging knowledge of overall corporate management based on ample experience at financial institutions, think tanks, and consulting firms.
He will have served as Outside Director who is an Audit and Supervisory Committee Member for two (2) years at the conclusion of this Annual General Meeting of Shareholders and has been renominated as candidate for Outside Director who is an Audit and Supervisory Committee Member in expectation of his further contribution going forward.</td></tr>
</table>

(Notes)

1. There is no special interest between the above candidates for Directors and the Company.
2. Mr. Ryuji Tomida, Ms. Ryoko Fukaya and Mr. Shigeki Moriguchi are candidates for Outside Directors.
3. The Company has entered into agreements with Mr. Ryuji Tomida, Ms. Ryoko Fukaya, and Mr. Shigeki Moriguchi to limit their liability for damages stipulated in Article 423, Paragraph 1 of the Companies Act pursuant to the provision of Article 427, Paragraph 1 of the said Act. The limit of liability under such agreement shall be the amount prescribed by laws and regulations. If the reelection of Mr. Tomida, Ms. Fukaya and Mr. Moriguchi is approved, the Company will continue the agreements under the same terms and conditions.
   The overview of the content of the agreement is as follows.
   • If a Director who is an Audit and Supervisory Committee Member is liable for any damage to the Company attributable to negligence of his/her duties, his/her liability shall be limited to the minimum liability amount specified in Article 425, Paragraph 1 of the Companies Act.
   • The aforementioned liability limitation shall be applied only in cases where such a Director who is an Audit and Supervisory Committee Member has executed his/her duties that have caused the liability in good faith and without gross negligence.
4. The Company has concluded a liability insurance contract with an insurance company for directors and officers. The relevant insurance policy covers damages and legal expenses incurred by the insured due to claims for damages arising from acts (including omissions) committed by the insured in connection with his/her duties as an officer of the Company. All insurance premiums are paid by the Company. If this proposal is approved and each candidate assumes the office of Director, he/she will be included as an insured person under the relevant insurance policy. In addition, the Company plans to renew the policy with the same contents at the next renewal.

(Reference) Skill matrix for the Board of Directors after the conclusion of this Annual General Meeting of Shareholders

Name	Position	Independent / Outside Directors	Term of office	Board of Directors	Nomination and Compensation Advisory Committee	Management	R&D / Clinical development	Manufacturing technology	Sales & marketing
Masahiko Miyata	Inside Director		30 years and 9 months	●	●	●	●		●
Kenji Miyata	Inside Director		25 years and 5 months	● (Chairperson)	●	●	●	●	
Makoto Nishiuchi	Inside Director		8 years	●			●		
Yoshinori Terai	Inside Director		13 years	●					●
Mizuho Ito	Inside Director		10 years	●	■ (Observer)				
Kazuhito Ishihara	Inside Director		2 years	●			●	●	
Shinjiro Otani	Inside Director		1 year	●	■ (Observer)			●	
Takahiro Kusakari	Outside Director	●	4 years	●	●	●			●
Akihiro Taguchi	Outside Director	●	3 years	●		●	●		●
Ryuji Tomida	Outside Director (Audit and Supervisory Committee Member)	●	8 years	●	● (Chairperson)				
Ryoko Fukaya	Outside Director (Audit and Supervisory Committee Member)	●	4 years	●	●				
Shigeki Moriguchi	Outside Director (Audit and Supervisory Committee Member)	●	2 years	●		●			●

Industry knowledge - medical devices	Industry knowledge - industrial devices	Quality assurance - pharmaceutical affairs	Finance & accounting	Risk management & legal affairs	Personnel management & development	DX / IT	Overseas experience	M&A	Equity market	Sustainability / ESG	Qualification
●						●	●		●		
	●	●		●	●		●		●		
●		●				●					
●							●	●			
			●	●				●	●	●	
●		●									
	●		●		●		●				
									●	●	
●		●					●		●		
				●	●			●			Lawyer
			●	●				●			Certified Public Accountant Certified Tax Accountant
			●	●	●						

Ratio of female Directors on the Board
16.7%
Female: 2 persons
Male: 10 persons

Ratio of Independent Outside Directors on the Board
41.7%
Independent Outside Directors: 5 persons
Inside Directors: 7 persons

Ratio of Independent Outside Directors at the Audit and Supervisory Committee
100%
Independent Outside Directors: 3 persons

Ratio of Independent Outside Directors at the Nomination and Compensation Advisory Committee
60.0%
Independent Outside Directors: 3 persons
Inside Directors: 2 persons

Corporate Governance System

In order to achieve continuous stable growth and expand corporate value, the Company believes that it is necessary to speed up decision-making and increase the transparency of its management. As such, management has placed the enhancement of corporate governance as a priority issue, and is working to improve corporate governance by focusing on the development of internal control systems, complying with laws, regulations, and the Articles of Incorporation, strengthening risk management, ensuring the timely and fair disclosure of information, and enhancing the executive officer system.

■ Corporate Governance System



(Note) The numbers of persons shown in the above chart are those as of September 29, 2026, assuming that the election of candidates for Director is approved at this General Meeting of Shareholders.

Proposal 4: Election of One (1) Director who is a Substitute Audit and Supervisory Committee Member

The election of Ms. Ayako Shimizu as a Director who is a Substitute Audit and Supervisory Committee Member, approved at the 48th Annual General Meeting of Shareholders held on September 26, 2024, will cease to be effective at the commencement of this Annual General Meeting of Shareholders. Accordingly, to prepare for a contingency in which the number of Audit and Supervisory Committee Members becomes less than the number required by laws and regulations, the Company proposes the election of one (1) Director who is a Substitute Audit and Supervisory Committee Member.

The effective term of a resolution for the election of a Director who is a Substitute Audit and Supervisory Committee Member shall be up to the conclusion of the Annual General Meeting of Shareholders held in the last fiscal year ending within two (2) years of his/her election. However, the election may be cancelled by resolution of the Board of Directors of the Company with the consent of the Audit and Supervisory Committee provided it is before the candidate assumes the office of Audit and Supervisory Committee Member.

The Audit and Supervisory Committee has previously given its consent regarding this Proposal.

The candidate for Director who is a Substitute Audit and Supervisory Committee Member is as follows:

Name (Date of birth)	Career summary, positions and responsibilities in the Company, and significant concurrent positions		Number of company shares held
Ayako Shimizu (June 6, 1972) [Outside] [Independent]	April 1999	Registered with Nagoya Bar Association (currently Aichi Bar Association) Joined Ishihara Law Office	0
	June 2014	Auditor of SYNCLAYER INC.	
	April 2015	Vice President of Aichi Bar Association Director of CHUBU Federation of Bar Associations	
	April 2017	Member of Nagoya City Information Disclosure Committee	
	July 2017	Member of Aichi Construction Dispute Committee	
	January 2018	Judicial Commissioner (current position)	
	April 2019	Mediator/Arbitrator of Aichi Bar Association Dispute Resolution Center (current position)	
	December 2019	Outside Director, Audit, Supervisory of MTG Co., Ltd.	
	April 2020	Member of Ombuds 6 Committee of Nagoya Broadcasting Network (current position)	
	June 2020	Outside Director of Aica Kogyo Company, Limited	
	March 2021	Outside Director (Audit and Supervisory Committee Member) of SYNCLAYER INC.	
	August 2021	Chairwoman of Aichi Construction Dispute Committee	
	September 2021	Member of Subcommittee on the Code of Civil Procedure (IT Transformation) of Legislative Council of the Ministry of Justice	
	June 2024	Outside Director (Audit and Supervisory Committee Member) of SUZUKEN CO., LTD. (current position)	
	September 2024	Substitute Audit and Supervisory Committee Member of the Company (current position)	
	April 2025	Member of Nagoya City Personal Information Protection Council (current position)	
	June 2025	Outside Auditor of AICHI ELECTRIC CO., LTD. (current position)	

[Matters regarding independence]

If the election of Ms. Ayako Shimizu is approved, the Company will register her as Independent Director stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange.

[Reason for nomination as candidate for Outside Director who is a Substitute Audit and Supervisory Committee Member and Overview of Expected Roles]

Ms. Ayako Shimizu has expertise and ample experience as a lawyer and is deemed appropriate to fulfill the duties of Outside Director who is an Audit and Supervisory Committee Member by providing advice for and checking on the Company’s business execution from the perspective of a legal expert. Accordingly, she has been nominated as candidate for Outside Director who is a Substitute Audit and Supervisory Committee Member.

(Notes)

1. There is no special interest between the above candidate for Outside Director who is a Substitute Audit and Supervisory Committee Member and the Company.
2. Ms. Ayako Shimizu is a candidate for Outside Director who is a Substitute Audit and Supervisory Committee Member.
3. Ms. Ayako Shimizu's name on the family register is Ayako Watanabe.
4. If the candidate Ms. Ayako Shimizu assumes the office of a Director who is an Audit and Supervisory Committee Member, the Company will enter into an agreement with her to limit her liability for damages stipulated in Article 423, Paragraph 1 of the Companies Act pursuant to the provision of Article 427, Paragraph 1 of the said Act. The limit of liability under such agreement shall be the amount prescribed by laws and regulations.
   The overview of the content of the agreement is as follows.
   - If a Director who is an Audit and Supervisory Committee Member is liable for any damage to the Company attributable to negligence of his/her duties, his/her liability shall be limited to the minimum liability amount specified in Article 425, Paragraph 1 of the Companies Act.
   - The aforementioned liability limitation shall be applied only in cases where such a Director who is an Audit and Supervisory Committee Member has executed his/her duties that have caused the liability in good faith and without gross negligence.
5. The Company has concluded a liability insurance contract with an insurance company for directors and officers. The relevant insurance policy covers damages and legal expenses incurred by the insured due to claims for damages arising from acts (including omissions) committed by the insured in connection with his/her duties as an officer of the Company. All insurance premiums are paid by the Company. If Ms. Ayako Shimizu assumes the office of Director who is an Audit and Supervisory Committee Member, she will be included as an insured person under the relevant insurance policy. In addition, the Company plans to renew the policy with the same contents at the next renewal.

Attachments

Business Report

(From July 1, 2025
to June 30, 2026)

1. Current State of the Corporate Group

1. Business progress and results

The Asahi Intecc Group aims to maintain a high level of growth and further enhance its corporate value by steadily promoting the growth strategies set forth in its new medium-term management plan, “Building the Future 2030,” which began in the fiscal year ended June 30, 2026.

The Group’s performance for the fiscal year ended June 30, 2026 progressed favorably, as follows.

Net sales amounted to 145,419 million yen (an increase of 21.2% year on year), driven by the strong performance of both the Medical and Device Divisions, as well as the impact of foreign exchange rates.

Gross profit totaled 102,447 million yen (an increase of 26.1% year on year), due to the increase in net sales, the impact of foreign exchange rates, and improvement in the gross profit margin in line with productivity improvements, despite an increase in U.S. tariffs.

Operating profit was 45,218 million yen (an increase of 50.3% year on year), due to the increase in net sales, productivity improvements, and the impact of foreign exchange rates, despite an increase in selling, general and administrative expenses, such as an increase in sales-related expenses aimed at strengthening sales in the U.S. and R&D expenses.

Ordinary profit was 45,185 million yen (an increase of 52.8% year on year), due to an increase in operating profit and a decrease in foreign exchange losses, despite a decrease in subsidy income.

Profit attributable to owners of parent was 32,075 million yen (an increase of 151.8% year on year), due to an increase in ordinary profit and a significant decrease in impairment losses.

	Fiscal year under review	Previous fiscal year	Increase (decrease) amount	Increase (decrease) rate
Net sales (Million yen)	145,419	120,025	25,394	21.2%
Operating profit (Million yen)	45,218	30,079	15,139	50.3%
Operating profit margin (%)	31.1	25.1	–	6.0%
Profit attributable to owners of parent (Million yen)	32,075	12,737	19,337	151.8%

Business results by segment were as follows.

(1) Medical Division

Development, manufacturing, and sales of minimally invasive treatment products (guide wires and catheters for treatments) mainly used for intravascular treatments

In the Medical Division, net sales increased in all regions, both in Japan and overseas.
In the domestic market, net sales increased mainly due to strong performance of purchased peripheral vascular products in the non-cardiovascular field.
In the overseas market, net sales increased in both the cardiovascular and non-cardiovascular fields, supported also by the impact of foreign exchange rates. In the cardiovascular field, net sales increased primarily for PCI guide wires and penetration catheters in all regions. In the non-cardiovascular field, net sales increased due to growth in abdominal and peripheral vascular products in all regions, as well as an increase in neurovascular products across overseas markets.
As a result, net sales totaled 126,798 million yen (an increase of 17.6% year on year).
Segment profit amounted to 46,190 million yen (an increase of 38.1% year on year).

Net sales composition ratio: 87.2%
Net sales: 126,798 million yen
Year-on-year: Up 17.6%

(2) Device Division

Development and manufacturing of components in the medical device field and industrial device field (including ultra-fine stainless-steel wire ropes), and sales of those products to manufacturers worldwide

In the Device Division, net sales increased due to the strong performance of both medical and industrial components, supported also by the impact of foreign exchange rates.
In addition, from the current fiscal year, Nitta Mold was included in the scope of consolidation as a consolidated subsidiary, and the company's profit and loss were reflected in the Group's consolidated results.
As for medical components, net sales increased mainly due to an increase in transactions in cardiovascular inspection catheter components for U.S. companies and transactions in cardiovascular ultrasound catheter components for Asia, as well as the consolidation of Nitta Mold as a subsidiary.
As for industrial components, net sales increased mainly due to an increase in leisure-related transactions in the overseas market and the consolidation of Nitta Mold as a subsidiary.
As a result, net sales totaled 18,620 million yen (an increase of 52.1% year on year).
Segment profit amounted to 8,485 million yen (an increase of 83.5% year on year), mainly due to an increase in revenues from external customers.

Net sales composition ratio: 12.8%
Net sales: 18,620 million yen
Year-on-year: Up 52.1%

2. State of assets and income

Item	47th Fiscal Year ended June 30, 2023	48th Fiscal Year ended June 30, 2024	49th Fiscal Year ended June 30, 2025	50th Fiscal Year ended June 30, 2026 (Fiscal year under review)
Net sales (Million yen)	90,101	107,547	120,025	145,419
Operating profit (Million yen)	18,030	22,135	30,079	45,218
Operating profit margin (%)	20.0	20.6	25.1	31.1
Ordinary profit (Million yen)	17,635	21,968	29,563	45,185
Profit attributable to owners of parent (Million yen)	13,106	15,808	12,737	32,075
Basic earnings per share (Yen)	48.25	58.20	46.92	120.59
R&D expenses (Million yen)	9,723	11,662	12,248	13,372
Ratio of R&D expenses to net sales (%)	10.8	10.8	10.2	9.2
Net assets (Million yen)	134,300	151,961	151,354	174,358
Total assets (Million yen)	172,644	191,614	193,187	218,285
ROE (%)	10.4	11.2	8.4	19.8
ROIC (%)	9.0	10.1	13.1	18.5

(Notes) 1. ROE (return on equity) is calculated based on the following formula:
ROE = profit attributable to owners of parent / equity (average of beginning and ending balances)

2. ROIC (return on invested capital) is calculated based on the following formula:
ROIC = net operating profit after tax / invested capital (interest-bearing liabilities＋shareholders’ equity (average of beginning and ending balances))

3. Issues to be addressed

(1) Management policy

The Asahi Intecc Group's mission is to supply the world with one-and-only technologies and number one products in the fields of medical devices and industrial components as an R&D company so that, based on safety and reliability, we realize dreams and contribute to society as a whole. In particular, in the Group's medical device field business, we develop, manufacture, and sell minimally invasive treatment products that reduce pain by minimizing the size of wounds. We believe that this is a business of great significance that reduces the physical, emotional, and economic burden on patients as well as contributes to curbing medical costs. We aim to grow further as a company highly recognized by society and the market with our commitment to be a company contributing to society.

(2) The Company's management strategy over the medium- and long-term

1) Promotion of the medium-term management plan

To realize its vision for 2035, the Asahi Intecc Group is advancing various strategies and initiatives based on the medium-term management plan "Building the Future 2030 – Unlocking Sustainable Growth," formulated in August 2025.

* Details of the medium-term management plan as a whole are provided in the separate document, "The 50th Annual General Meeting of Shareholders: Other Matters Subject to the Electronic Provision Measures (Matters for Which Document Delivery is Omitted)."

(Progress of the medium-term management plan)

Since the formulation of the medium-term management plan, market share expansion across regions and businesses has progressed steadily, and the net sales target is expected to be achieved ahead of the original schedule. In addition, profitability has exceeded the assumptions made when the plan was formulated, as productivity improvements at overseas factories have progressed beyond initial expectations.

(Revision of numerical targets)

Based on this progress in business activities and recent foreign exchange trends, the Group has revised upward the numerical targets for the fiscal year ending June 30, 2030, the final year of the medium-term management plan, and has also revised the numerical targets set forth in its long-term vision.

The main revisions are increases in net sales and profit levels. The Group has also revised its targets related to capital efficiency.

(Revised numerical targets)

Final year of the medium-term management plan (Fiscal year ending June 30, 2030)	Initial targets	Revised targets
Net sales	180.0 billion yen	212.5 billion yen
Gross profit margin	69.0%	72.5%
Operating profit	50.4 billion yen	68.0 billion yen
Operating profit margin	28.0%	32.0%
ROE	16.0%	20.0%
ROIC	16.0%	19.0%

Long-term vision	Initial targets	Revised targets
Net sales	300.0 billion yen	330.0 billion yen
Operating profit margin	30.0%	33.0%

(Future policy)

This revision does not change the long-term direction pursued by the Group or the basic policies and growth strategies set forth in the medium-term management plan. The Group will continue to steadily promote its strategies and measures, aiming to achieve sustainable growth and enhance corporate value over the medium to long term.

4. State of capital investment and financing

(1) Capital investment

The total amount of capital investment conducted during the fiscal year under review was 9,631 million yen.

Capital investments included enhancement of production facilities at overseas production subsidiaries (Note 1) and enhancement of R&D facilities at R&D bases (Note 2) in and outside of Japan, which can be broken down to 5,368 million yen for the Medical Division, 3,393 million yen for the Device Division, and 869 million yen for the Headquarters (administrative divisions).

Note 1: ASAHI INTECC THAILAND CO., LTD. (Thailand Factory), ASAHI INTECC HANOI CO., LTD. (Hanoi Factory), TOYOFLEX CEBU CORPORATION (Cebu Factory), and Asahi Intecc Medical Device (Nanning) Co., Ltd. (Nanning Factory) (scheduled to commence operations in 2030)

Note 2: Global Headquarters and R&D Center, Osaka R&D Center, Shizuoka R&D Center, Tohoku R&D Center, Tokyo R&D Center, ASAHI INTECC THAILAND CO., LTD. (Thailand Factory), and ASAHI INTECC USA, INC.

(2) Financing

During the fiscal year under review, there was no financing to be noted.

5. State of business transfers or successions, mergers or company splits, and acquisitions or disposals of shares

Not applicable.

6. State of significant subsidiaries

Company name [Location]	Capital stock	The Company's voting rights ratio (%)	Description of principal businesses
ASAHI INTECC THAILAND CO., LTD. [Pathum Thani, Thailand]	270,000 thousand THB	100.0	Development, manufacturing, and sales of components and other products for medical devices and industrial devices
ASAHI INTECC HANOI CO., LTD. [Hanoi, Vietnam]	39,000 thousand USD	100.0	Manufacturing of medical devices
TOYOFLEX CEBU CORPORATION [Cebu, The Philippines]	664,300 thousand PHP	100.0	Manufacturing of components and other products for medical devices and industrial devices
Filmecc Co., Ltd. [Seto-shi, Aichi]	99 million yen	100.0	Development, manufacturing and sales of medical devices
ASAHI INTECC J-Sales, INC. [Minato-ku, Tokyo]	200 million yen	100.0	Sales of medical devices
ASAHI INTECC USA, INC. [California, U.S.A.]	5 thousand USD	100.0	Development and sales of medical devices
Filmecc USA, Inc. [California, U.S.A.]	300 thousand USD	100.0 [100.0]	Sales of OEM and ODM medical devices, etc.
ASAHI INTECC SCIENTIFIC (Beijing) Co., Ltd. [Beijing, China]	5,000 thousand CNY	100.0	Sales of medical devices
ASAHI INTECC EUROPE B.V. [Amsterdam, The Netherlands]	300 thousand EUR	100.0	Sales of medical devices

* The figure in brackets in the "The Company's voting rights ratio (%)" column indicates the percentage held indirectly.

2. Company Officers

1. Names and details of Directors

(As of June 30, 2026)

Position	Name	Responsibilities and significant concurrent positions
Chairman and Director	Masahiko Miyata	Chairman of the Medical Technology Association of Japan Vice Chairman of the Japan Federation of Medical Devices Associations
President & CEO	Kenji Miyata	CEO Chairman and Director of ASAHI INTECC HANOI CO., LTD.
Executive Director	Makoto Nishiuchi	General Manager of Medical Business Division General Manager of Medical Brand Business Unit of Medical Business Division CDO (Chief Digital Officer)
Director	Yoshinori Terai	General Manager of New Business Development Division President & CEO of ASAHI INTECC USA, INC.
Director	Mizuho Ito	CFO General Manager of Administration Division General Manager of Corporate Strategic Office
Director	Kazuhito Ishihara	Deputy Supervisor of Research and Development of Medical Brand Business Unit of Medical Business Division
Director	Shinjiro Otani	General Manager of Human Resources Development Division Group Manager of Human Resources Development Group
Director	Takahiro Kusakari	
Director	Akihiro Taguchi	Outside Director of MIRAINI HOLDINGS CO., LTD.
Director (Audit and Supervisory Committee Member)	Ryuji Tomida	Lawyer Chairperson of Aichi Prefectural Labour Relations Commission
Director (Audit and Supervisory Committee Member)	Ryoko Fukaya	Certified Public Accountant Certified Tax Accountant Outside Director (Audit and Supervisory Committee Member) of Aica Kogyo Company, Limited
Director (Audit and Supervisory Committee Member)	Shigeki Moriguchi	

(Notes)
1. Directors Takahiro Kusakari and Akihiro Taguchi are Outside Directors, and they are Independent Directors stipulated in the listing regulations established by the Tokyo Stock Exchange and Nagoya Stock Exchange.
2. Directors (Audit and Supervisory Committee Members) Ryuji Tomida, Ryoko Fukaya and Shigeki Moriguchi are Outside Directors (Audit and Supervisory Committee Members), and they are Independent Directors stipulated in the listing rules of the Tokyo Stock Exchange and Nagoya Stock Exchange.
3. Director (Audit and Supervisory Committee Member) Ryoko Fukaya has considerable knowledge of finance and accounting as a certified public accountant and certified tax accountant.
4. Employees of the Internal Audit Office are designated as assistants to the Audit and Supervisory Committee. They collect information on a daily basis, such as by attending important meetings and inspecting important documents, and conduct periodic hearings, etc. from operating divisions. In addition, the Audit and Supervisory Committee ensures the effectiveness of audits by combining organizational audits using the Internal Control Systems and audit activities conducted by the Committee itself as needed. Accordingly, the Company does not appoint a Full-Time Audit and Supervisory Committee Member.

2. Outline of liability limitation agreements

The Company and its Directors (excluding executive Directors) have entered into liability limitation agreements to limit the liabilities for damages stipulated in Article 423, Paragraph 1 of the Companies Act to the minimum amount of liabilities specified in Article 425, Paragraph 1 of the said Act, pursuant to the provisions of Article 427, Paragraph 1 of the said Act.

3. Outline of the directors and officers liability insurance agreement

(1) Scope of the insured

Directors and important employees of the Company and officers of its subsidiaries are specified as the insured.

(2) Outline of the insurance policy

The relevant insurance policy covers damages and legal expenses incurred by the insured due to claims for damages arising from acts (including omissions) committed by the insured in connection with his/her duties as a corporate officer. All insurance premiums are paid by the Company. The policy excludes certain cases from its coverage, including criminal acts such as bribery, as well as damages incurred by officers who intentionally performed unlawful acts, so that the properness of the execution of duties by Directors and officers is not hindered.

4. Remuneration of Directors

(1) Details of the policy for determining the amounts of remuneration of officers or the method of calculating the amounts, and the method of determining the said policy

The total amount of remuneration of Directors was determined at the 40th Annual General Meeting of Shareholders held on September 28, 2016 to be no more than 1,000 million yen per year for Directors (excluding Directors who are Audit and Supervisory Committee Members), including 100 million yen per year for Outside Directors, and no more than 40 million yen per year for Directors who are Audit and Supervisory Committee Members. Remuneration of each Director is determined pursuant to the following policy within the limits of this total amount. The number of Directors (excluding Directors who are Audit and Supervisory Committee Members) elected at the 40th Annual General Meeting of Shareholders was nine (including two Outside Directors), and the number of Directors who are Audit and Supervisory Committee Members was three. The Board of Directors of the Company has passed a resolution on the following policy. The Board of Directors of the Company has confirmed that the method of determining the contents of individual remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members) pertaining to the fiscal year under review, as well as the contents of the determined remuneration, are in line with the following policy.

1) Policy for determining the overall remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members)

The Board of Directors determines the total amount of each type of remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members) within the limits of total amount of remuneration determined by a resolution of the General Meeting of Shareholders, upon receiving reports from the Nomination and Compensation Advisory Committee. The Nomination and Compensation Advisory Committee consists of three or more members who are Directors selected by a resolution of the Board of Directors. A majority of the members are selected from among Independent Outside Directors, and at least one of those Independent Outside

Directors must be a Director who is an Audit and Supervisory Committee Member. The types of remuneration are base remuneration, performance-linked remuneration (Director bonuses commensurate with short-term results), and remuneration for share purchase (linked to improvements in long-term performance).

2) Policy on determining the amounts of base remuneration and remuneration for share purchase (linked to improvements in long-term performance), which are components of remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members)

Amounts to be paid as the base remuneration component and the remuneration for share purchase component (linked to improvements in long-term performance) are determined in consideration of each Director's position, duties, and tenure, as well as the state of the Asahi Intecc Group.

3) Policy on determining the amount of performance-linked remuneration (Director bonuses commensurate with short-term results), which is a component of remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members)

The performance-linked remuneration component (Director bonuses commensurate with short-term results) is paid in consideration of each Director's position, duties, and tenure, only when the consolidated performance of the Company is expected to exceed the sales and profit plan disclosed to the public by a considerable margin, using a portion of the excess as the source of remuneration.

4) Policy on determining the timing of remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members)

The base remuneration component and the remuneration for share purchase component (linked to improvements in long-term performance) are paid monthly. If the performance-linked remuneration component (Director bonuses commensurate with short-term results) is to be paid, the payment is made once a year within three months from the end of a fiscal year.

5) Policy on determining the ratio of base remuneration, remuneration for share purchase (linked to improvements in long-term performance), and performance-linked remuneration (Director bonuses commensurate with short-term results), which are components of remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members), in individual remuneration of Directors

The ratio of remuneration is determined by the Board of Directors (President & CEO who has been delegated the authority as per 6) below) upon receiving reports from the Nomination and Compensation Advisory Committee.

6) Policy on determining the contents of individual remuneration of Directors (excluding Directors who are Audit and Supervisory Committee Members)

President & CEO Kenji Miyata, who has been delegated the authority by the Board of Directors, determines the amounts of the base remuneration component, the remuneration for share purchase component (linked to improvements in long-term performance), and the performance-linked remuneration component (Director bonuses commensurate with short-term results) paid to each individual, in compliance with the basic policy passed by a resolution of the Board of Directors upon receiving reports from the Nomination and Compensation Advisory Committee. The reason for the delegation to the President & CEO is because the President & CEO, who is in a position to oversee the business execution of the entire Company and maintain a complete picture of the Company's performance, is best suited to evaluate each Director.

7) Remuneration of Directors who are Audit and Supervisory Committee Members

Remuneration of Directors who are Audit and Supervisory Committee Members is determined by discussion among Directors who are Audit and Supervisory Committee Members, within the limits of total amount of remuneration determined by a resolution of the General Meeting of Shareholders.

(2) Amounts of remuneration of Directors

Category	Number of eligible Directors (persons)	Total amount of remuneration (Million yen)			
			Total amount of base remuneration component	Total amount of remuneration for share purchase component	Total amount of performance-linked remuneration component
Directors (excluding Audit and Supervisory Committee Members) (of which, Outside Directors)	11 (3)	647 (20)	365 (14)	35 (1)	246 (4)
Directors (Audit and Supervisory Committee Members) (of which, Outside Directors)	3 (3)	29 (29)	26 (26)	2 (2)	- (-)
Total	14	676	392	37	246

(Notes) 1. The above amounts include remuneration paid to two Directors (excluding Audit and Supervisory Committee Members) who retired at the conclusion of the 49th Annual General Meeting of Shareholders held on September 25, 2025 and to one Director (excluding Audit and Supervisory Committee Member) who assumed the office at the 49th Annual General Meeting of Shareholders held on September 25, 2025.
2. The remuneration for share purchase component is remuneration linked to improvements in long-term performance.
3. The performance-linked remuneration component is Director bonuses commensurate with short-term results.

5. Outside Directors

(1) Relationships between the Company and companies at which Outside Directors hold significant concurrent positions

Not applicable.

(2) Main activities during the fiscal year under review

Category	Name	State of activities
Director	Takahiro Kusakari	He attended 13 out of 13 meetings of the Board of Directors held during the fiscal year under review, and made remarks that contribute to the enhancement of the Company’s corporate value based on his past experience as Fund Manager and Chief Investment Officer of an investment trust management firm. In addition, he has served as a member of the Nomination and Compensation Advisory Committee, established for the purpose of ensuring fairness and objectivity in nomination and remuneration of Directors.
Director	Akihiro Taguchi	He attended 13 out of 13 meetings of the Board of Directors held during the fiscal year under review, and made remarks that contribute to the enhancement of the Company’s corporate value based on his ample experience in the medical industry.
Director (Audit and Supervisory Committee Member)	Ryuji Tomida	He attended 13 out of 13 meetings of the Board of Directors and 14 out of 14 meetings of the Audit and Supervisory Committee held during the fiscal year under review, and made remarks on legal affairs and risk management primarily from a professional standpoint as a lawyer. In addition, he serves as a member of the Nomination and Compensation Advisory Committee, established for the purpose of ensuring fairness and objectivity in nomination and remuneration of Directors.
Director (Audit and Supervisory Committee Member)	Ryoko Fukaya	She attended 13 out of 13 meetings of the Board of Directors and 14 out of 14 meetings of the Audit and Supervisory Committee held during the fiscal year under review, and made remarks on corporate finance and corporate governance primarily from a professional standpoint, by leveraging various working experiences as a certified public accountant. In addition, she has served as a member of the Nomination and Compensation Advisory Committee, established for the purpose of ensuring fairness and objectivity in nomination and remuneration of Directors.
Director (Audit and Supervisory Committee Member)	Shigeki Moriguchi	He attended 13 out of 13 meetings of the Board of Directors and 14 out of 14 meetings of the Audit and Supervisory Committee held during the fiscal year under review, and made remarks on corporate finance and corporate governance primarily based on his ample experience at financial institutions, think tanks, and consulting firms.

The Company's Website

Information disclosed by the Company is available from the following URLs.
Please visit them to learn more about our initiatives as an accompaniment to this Notice of Convocation.

►Materials related to shareholders' meetings
Including notices of convocation and notices of resolutions
> Please visit the **"Shareholders' meeting"** page
URL: https://ir.asahi-intecc.co.jp/en/ir/stock/meeting.html

►IR materials

> Please visit the **"IR Library"** page
URL: https://ir.asahi-intecc.co.jp/en/ir/irlibrary.html

►Materials related to financial results
> Please visit the **"Financial Statements"** page
URL: https://ir.asahi-intecc.co.jp/en/ir/irlibrary/results.html

> Please visit the **"Annual Securities Report"** page (available only in Japanese)
URL: https://ir.asahi-intecc.co.jp/en/ir/irlibrary/securities.html

> Please visit the **"Financial Results Presentation Materials"** page
URL: https://ir.asahi-intecc.co.jp/en/ir/irlibrary/presentation.html

►Other IR materials
> Please visit the **"Integrated Report"** page
URL: https://www.asahi-intecc.co.jp/en/esg#integrated_report

> Please visit the **"Mid-Term Management Plan"** page
URL: https://ir.asahi-intecc.co.jp/en/ir/irlibrary/plan.html